Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Avacta Group shares rally 6% after distribution pact with ABCAM

Published 06/04/2021, 09:49
Updated 06/04/2021, 09:52
© Reuters

© Reuters

By Samuel Indyk

Investing.com – Avacta Group PLC (LON:AVTG) announced on Tuesday that they have entered into a global distribution agreement with Abcam PLC (LON:ABCA) to sell its Covid-19 research ELISA affirmer reagents.

The UK-listed diagnostics company developed its Affirmer reagents which can be used in ELISA laboratory tests to detect the Covid-19 spike protein with high sensitivity and excellent specificity for the spike protein of the original strain of the virus and other dominant variants, including the Kent variant.

About ABCAM

The UK-based, dual-listed company supplies high quality biological reagents and kits which are used in diagnostics and basic research. Under the agreement with Avacta, Abcam PLC (NASDAQ:ABCM) will enable the global research community to access Avacta’s spike protein Affirmer research reagents through its online catalogue, allowing scientists around the world to perform the ELISA test in their own laboratories.

Financial terms of the worldwide, non-exclusive distribution agreement between the two companies have not been disclosed.

“We are delighted that we have established a global route to market for the SARS-CoV-2 spike protein Affimer reagents through ABCAM's dedicated global commercialisation infrastructure,” said Avacta Group CEO Dr Alastair Smith.

“As far as we are aware, our spike protein ELISA test is the most sensitive test of its kind and, in ABCAM, we have a world-leading partner capable of maximising the commercial potential of the Affimer reagents by making them globally available to scientists who are researching into the SARS-CoV-2 coronavirus.”

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.